Home
/
ORAMED PHARMACEUTICALS INC.
/
Financials
/
Quarterly
ORAMED PHARMACEUTICALS INC. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that ORAMED PHARMACEUTICALS INC. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$2.00M
Nov 13, 2025
Q2
2025
Jun 30, 2025
$2.00M
Aug 14, 2025
Q1
2025
Mar 31, 2025
$2.00M
May 15, 2025
Q3
2024
Sep 30, 2023
$1.34M
Nov 7, 2024
Q2
2024
Jun 30, 2023
$674.0K
Aug 14, 2024
Q1
2024
Mar 31, 2023
$666.0K
May 9, 2024
Q3
2023
Sep 30, 2022
$682.0K
Nov 9, 2023
Q2
2023
Jun 30, 2022
$674.0K
Aug 10, 2023
Q1
2023
Mar 31, 2022
$666.0K
May 11, 2023
Q1
2022
Nov 30, 2021
$674.0K
Jan 11, 2022
Q3
2022
Sep 30, 2021
$682.0K
Nov 10, 2022
Q2
2022
Jun 30, 2021
$674.0K
Aug 10, 2022
Q3
2021
May 31, 2021
$681.0K
Jul 14, 2021
Q1
2022
Mar 31, 2021
$666.0K
May 12, 2022
Q2
2021
Feb 28, 2021
$665.0K
Apr 13, 2021
Q1
2022
Nov 30, 2020
$674.0K
Jan 11, 2022
Q3
2021
May 31, 2020
$681.0K
Jul 14, 2021
Q2
2021
Feb 29, 2020
$674.0K
Apr 13, 2021
Q1
2021
Nov 30, 2019
$674.0K
Jan 14, 2021
Q3
2020
May 31, 2019
$682.0K
Jul 7, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$48.40M
Nov 13, 2025
Q2
2025
Jun 30, 2025
$13.29M
Aug 14, 2025
Q1
2025
Mar 31, 2025
($7.64M)
May 15, 2025
Q3
2025
Sep 30, 2024
($19.62M)
Nov 13, 2025
Q2
2025
Jun 30, 2024
$9.21M
Aug 14, 2025
Q1
2025
Mar 31, 2024
$1.54M
May 15, 2025
Q3
2024
Sep 30, 2023
($3.22M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($1.19M)
Aug 14, 2024
Q1
2024
Mar 31, 2023
($3.40M)
May 9, 2024
Q3
2023
Sep 30, 2022
($7.06M)
Nov 9, 2023
Q2
2023
Jun 30, 2022
($10.53M)
Aug 10, 2023
Q1
2022
Mar 31, 2022
($10.71M)
May 12, 2022
Q1
2022
Nov 30, 2021
($8.10M)
Jan 11, 2022
Q2
2022
Jun 30, 2021
($3.91M)
Aug 10, 2022
Q3
2021
May 31, 2021
($5.21M)
Jul 14, 2021
Q1
2022
Mar 31, 2021
($6.06M)
May 12, 2022
Q2
2021
Feb 28, 2021
($4.61M)
Apr 13, 2021
Q1
2022
Nov 30, 2020
($5.57M)
Jan 11, 2022
Q3
2021
May 31, 2020
($2.28M)
Jul 14, 2021
Q2
2021
Feb 29, 2020
($3.69M)
Apr 13, 2021
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($2.43M)
Nov 13, 2025
Q2
2025
Jun 30, 2025
($2.49M)
Aug 14, 2025
Q1
2025
Mar 31, 2025
($4.50M)
May 15, 2025
Q3
2025
Sep 30, 2024
($3.09M)
Nov 13, 2025
Q2
2025
Jun 30, 2024
($3.14M)
Aug 14, 2025
Q1
2025
Mar 31, 2024
($2.96M)
May 15, 2025
Q3
2024
Sep 30, 2023
($2.89M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($3.79M)
Aug 14, 2024
Q1
2024
Mar 31, 2023
($5.21M)
May 9, 2024
Q3
2023
Sep 30, 2022
($8.19M)
Nov 9, 2023
Q2
2023
Jun 30, 2022
($11.42M)
Aug 10, 2023
Q1
2023
Mar 31, 2022
($11.25M)
May 11, 2023
Q1
2022
Nov 30, 2021
($8.06M)
Jan 11, 2022
Q3
2022
Sep 30, 2021
($7.49M)
Nov 10, 2022
Q2
2022
Jun 30, 2021
($4.45M)
Aug 10, 2022
Q3
2021
May 31, 2021
($6.12M)
Jul 14, 2021
Q1
2022
Mar 31, 2021
($6.60M)
May 12, 2022
Q2
2021
Feb 28, 2021
($4.87M)
Apr 13, 2021
Q1
2022
Nov 30, 2020
($5.83M)
Jan 11, 2022
Q3
2021
May 31, 2020
($2.27M)
Jul 14, 2021